MCL1 and hepatocellular carcinoma: Sorafenib has been described as an apoptosis inducer in HCC cells, through upregulation of proapoptotic PUMA and BIM, downregulation of antiapoptotic Mcl-1, activation of BAX and BAK, release of cytochrome c, and increase in Caspase-3 function [102].